Preclinical research shows that COVID-19 infection may dysregulate NAD+ synthesis

Reposted from Nutritional Outlook

nutritionaloutlook.jpg
 

A new preclinical study found that SARS-CoV-2 (the virus that causes COVID-19) infection of cell lines, infected ferrets, and a deceased patient’s lung dysregulates nicotinamide adenine dinucleotide (NAD+) synthesis and utilization. Explaining the findings that led to this current preclinical study, Charles Brenner, PhD, chief scientific advisor to ChromaDex (Los Angeles, CA), and co-author of the study states: “We started by looking at the effect of a related coronavirus that infects mice. It disturbs the gene set that controls cellular NAD. Moreover, we showed that within 12 hours of initial infection, the virus greatly depresses levels of NAD, the central catalyst of metabolism.”

In The NewsANAD Staff